BRPI0923903B8 - derivados de piridazinona, e medicamentos. - Google Patents

derivados de piridazinona, e medicamentos.

Info

Publication number
BRPI0923903B8
BRPI0923903B8 BRPI0923903A BRPI0923903A BRPI0923903B8 BR PI0923903 B8 BRPI0923903 B8 BR PI0923903B8 BR PI0923903 A BRPI0923903 A BR PI0923903A BR PI0923903 A BRPI0923903 A BR PI0923903A BR PI0923903 B8 BRPI0923903 B8 BR PI0923903B8
Authority
BR
Brazil
Prior art keywords
drugs
pyridazinone derivatives
inhibitors
compounds
pyridazinone
Prior art date
Application number
BRPI0923903A
Other languages
English (en)
Inventor
Blaukat Andree
Dorsch Dieter
Stieber Frank
Schadt Oliver
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0923903A2 publication Critical patent/BRPI0923903A2/pt
Publication of BRPI0923903B1 publication Critical patent/BRPI0923903B1/pt
Publication of BRPI0923903B8 publication Critical patent/BRPI0923903B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

derivados de piridazinona. a presente invenção refere-se a compostos da fórmula (l), em que d, r1, r2, r3, r4 têm os significados indicados na reivindicações 1. os compostos de acordo com a invenção são inibidores de tirosina quinases, especialmente inibidores de met quinase e podem ser empregados, inter alia, para o tratamento de tumores.
BRPI0923903A 2009-01-08 2009-12-10 derivados de piridazinona, e medicamentos. BRPI0923903B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009004061.7 2009-01-08
DE102009004061A DE102009004061A1 (de) 2009-01-08 2009-01-08 Pyridazinonderivate
PCT/EP2009/008839 WO2010078909A1 (de) 2009-01-08 2009-12-10 Pyridazinonderivate

Publications (3)

Publication Number Publication Date
BRPI0923903A2 BRPI0923903A2 (pt) 2015-07-28
BRPI0923903B1 BRPI0923903B1 (pt) 2020-03-24
BRPI0923903B8 true BRPI0923903B8 (pt) 2021-05-25

Family

ID=41581157

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923903A BRPI0923903B8 (pt) 2009-01-08 2009-12-10 derivados de piridazinona, e medicamentos.

Country Status (24)

Country Link
US (1) US8623870B2 (pt)
EP (1) EP2373647B1 (pt)
JP (1) JP5683488B2 (pt)
KR (1) KR101669696B1 (pt)
CN (1) CN102272131A (pt)
AR (1) AR074997A1 (pt)
AU (1) AU2009336851B2 (pt)
BR (1) BRPI0923903B8 (pt)
CA (1) CA2749015C (pt)
CY (1) CY1113700T1 (pt)
DE (1) DE102009004061A1 (pt)
DK (1) DK2373647T3 (pt)
EA (1) EA020574B1 (pt)
ES (1) ES2398023T3 (pt)
HR (1) HRP20120976T1 (pt)
IL (1) IL213826A (pt)
MX (1) MX2011007209A (pt)
PL (1) PL2373647T3 (pt)
PT (1) PT2373647E (pt)
SG (1) SG172458A1 (pt)
SI (1) SI2373647T1 (pt)
SM (1) SMT201300010B (pt)
WO (1) WO2010078909A1 (pt)
ZA (1) ZA201105781B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN117126150A (zh) * 2023-08-29 2023-11-28 仁合益康集团有限公司 一种阿齐沙坦酯钾盐杂质a的制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5795964A (en) 1980-12-04 1982-06-15 Morishita Seiyaku Kk Preparation of 2-substituted-3(2h)-pyridazinone derivative
US4397854A (en) 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
AU691673B2 (en) 1994-11-14 1998-05-21 Dow Agrosciences Llc Pyridazinones and their use as fungicides
US5635494A (en) 1995-04-21 1997-06-03 Rohm And Haas Company Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US6348468B1 (en) 1997-11-19 2002-02-19 Kowa Co., Ltd. Pyridazine compounds and compositions containing the same
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
US20040259863A1 (en) 2001-10-31 2004-12-23 Hans-Michael Eggenweiler Type 4 phosphodiesterase inhibitors and uses thereof
AU2002346475A1 (en) 2001-12-05 2003-06-23 Ortho-Mcneil Pharmaceutical, Inc. 6-o-acyl ketolide derivatives of erythromycine useful as antibacterials
WO2005121132A1 (ja) 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗ｈｃｖ作用を有する縮合ヘテロ環化合物
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
PL1959955T3 (pl) 2005-12-05 2011-04-29 Pfizer Prod Inc Sposób traktowania nieprawidłowego wzrostu komórek
DE102006037478A1 (de) 2006-08-10 2008-02-14 Merck Patent Gmbh 2-(Heterocyclylbenzyl)-pyridazinonderivate
TW200845991A (en) * 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
DE102007061963A1 (de) * 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
EP2379547A1 (en) * 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
DE102009003954A1 (de) * 2009-01-07 2010-07-08 Merck Patent Gmbh Pyridazinonderivate

Also Published As

Publication number Publication date
EA020574B1 (ru) 2014-12-30
DK2373647T3 (da) 2012-12-10
KR101669696B1 (ko) 2016-10-27
WO2010078909A1 (de) 2010-07-15
EP2373647B1 (de) 2012-10-31
CY1113700T1 (el) 2016-06-22
CN102272131A (zh) 2011-12-07
HRP20120976T1 (hr) 2012-12-31
MX2011007209A (es) 2011-08-04
SG172458A1 (en) 2011-08-29
JP5683488B2 (ja) 2015-03-11
ZA201105781B (en) 2012-04-25
DE102009004061A1 (de) 2010-07-15
BRPI0923903B1 (pt) 2020-03-24
EP2373647A1 (de) 2011-10-12
IL213826A (en) 2016-07-31
AU2009336851A1 (en) 2011-08-25
US20110269771A1 (en) 2011-11-03
CA2749015C (en) 2017-10-31
PL2373647T3 (pl) 2013-03-29
CA2749015A1 (en) 2010-07-15
IL213826A0 (en) 2011-07-31
KR20110099799A (ko) 2011-09-08
AR074997A1 (es) 2011-03-02
ES2398023T3 (es) 2013-03-13
US8623870B2 (en) 2014-01-07
PT2373647E (pt) 2013-01-30
AU2009336851B2 (en) 2016-03-03
JP2012514612A (ja) 2012-06-28
SI2373647T1 (sl) 2013-01-31
BRPI0923903A2 (pt) 2015-07-28
SMT201300010B (it) 2013-03-08
EA201101038A1 (ru) 2012-01-30

Similar Documents

Publication Publication Date Title
BRPI0911161B8 (pt) derivados de piridazinona e seu processo de preparação
UA99621C2 (xx) Похідні піридазинону$производные пиридазинона
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
MX2009013077A (es) Derivados dde benzoxazolona.
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
MX2008005398A (es) Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
BR112012010186B8 (pt) derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos
EA200901601A1 (ru) Производные пиридазинона
EA201100966A1 (ru) Производные пиридазинона
BR112014005226A2 (pt) derivados de benzonitrila como inibidores de cinase
UA95934C2 (ru) Производные пиридиазинона для лечения опухолей
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
EA200901603A1 (ru) Арил-эфирные производные пиридазинона
UA99311C2 (en) Inhibitors of c-fms kinase
JO3073B1 (ar) مثبطات ثنائية ملتحمة ثلاثية الحلقة ل cdk 4/6 و flt3
EA201100334A1 (ru) Бициклические производные триазола для лечения опухолей
MX2011007165A (es) Derivados de piridazinona.
MX2009011964A (es) Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico.
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MY155230A (en) Sulfoximine-substituted aniline pyrimidine derivatives as cdk inhibitors, their manufacture and use as medicine
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
MX2011007232A (es) Derivados de benzotiazolona.
BRPI0923903B8 (pt) derivados de piridazinona, e medicamentos.
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2804 DE 01-10-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.